Wolfe Research Downgrades Spyre Therapeutics to Peer Perform
Wolfe Research analyst Andy Chen downgrades Spyre Therapeutics (NASDAQ:SYRE) from Outperform to Peer Perform.
A well-known analyst (think of them like a sports scout) changed their opinion about Spyre Therapeutics from "really good" to "average" compared to similar companies. When smart analysts become less excited about a company, it's worth noticing what changed in their thinking.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.